tiprankstipranks
Advertisement
Advertisement
Mesoblast Showcases Profitable Ryoncil Launch and Expanding Cell Therapy Pipeline in June 2026 CEO Presentation
PremiumCompany AnnouncementsMesoblast Showcases Profitable Ryoncil Launch and Expanding Cell Therapy Pipeline in June 2026 CEO Presentation
1M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
2M ago
Mesoblast Details April Equity Issuance Moves and Director Share Purchases
Premium
Company Announcements
Mesoblast Details April Equity Issuance Moves and Director Share Purchases
3M ago
Mesoblast reports March quarter Ryoncil sales of $30.3M
PremiumThe FlyMesoblast reports March quarter Ryoncil sales of $30.3M
3M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
4M ago
Mesoblast Grants New Director Options Following 2025 AGM Approvals
Premium
Company Announcements
Mesoblast Grants New Director Options Following 2025 AGM Approvals
4M ago
Mesoblast Touts Ryoncil Survival Data, Prepares Adult SR-aGvHD Pivotal Trial
PremiumCompany AnnouncementsMesoblast Touts Ryoncil Survival Data, Prepares Adult SR-aGvHD Pivotal Trial
5M ago
Mesoblast Lifts Ryoncil Revenues, Secures Cheaper Credit and Advances Late-Stage Cell Therapy Pipeline
Premium
Company Announcements
Mesoblast Lifts Ryoncil Revenues, Secures Cheaper Credit and Advances Late-Stage Cell Therapy Pipeline
6M ago
Mesoblast Reports 84% Survival in Early Real‑World Use of Ryoncil for Pediatric SR‑aGvHD
Premium
Company Announcements
Mesoblast Reports 84% Survival in Early Real‑World Use of Ryoncil for Pediatric SR‑aGvHD
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100